Systemic lupus erythematosus (SLE) is a multisystem, chronic autoimmune disease where
treatment varies by patient and disease activity. Strong preclinical results and clinical …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by excessive
autoantibody production and multi-organ involvement. Although the etiology of SLE still …

The B cell activating factor (BAFF) inhibitor, belimumab, is the first biologic drug approved for
the treatment of SLE, and exhibits modest, but durable, efficacy in decreasing disease flares …

Belimumab has therapeutic benefit in active systemic lupus erythematosus (SLE), especially
in patients with high-titer anti-dsDNA antibodies. We asked whether the profound B cell loss …

Objective To characterize renal macrophages and dendritic cells (DCs) in 2 murine models
of lupus nephritis. Methods We used a bead‐based enrichment step followed by cell sorting …

Most B cells produced in the bone marrow have some level of autoreactivity. Despite efforts
of central tolerance to eliminate these cells, many escape to periphery, where in healthy …

Germinal centers (GCs) are the primary site at which clonal expansion and affinity
maturation of B cells occur. B cells encounter antigen and receive T cell help in the GC light …

Aging negatively affects B cell production, resulting in a decrease in B-1 and B-2 cells and
impaired antibody responses. Age-related B cell subsets contribute to inflammation …

IgG antinuclear antibodies (ANAs) are a dominant feature of several autoimmune diseases.
We previously showed that systemic lupus erythematosus (SLE) is characterized by …

BAFF (B-cell–activating factor) is a critical survival factor for transitional and mature B cells
and is a promising therapeutic target for systemic lupus erythematosus (SLE). In 2010–2011 …